Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OSUR 
OraSure Technologies Inc (OSUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: OSUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.83% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 223.07M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 4 | Beta 0.46 | 52 Weeks Range 2.36 - 4.60 | Updated Date 10/14/2025 |
52 Weeks Range 2.36 - 4.60 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -36.84% | Operating Margin (TTM) -55.35% |
Management Effectiveness
Return on Assets (TTM) -7.24% | Return on Equity (TTM) -12.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8465769 | Price to Sales(TTM) 1.61 |
Enterprise Value 8465769 | Price to Sales(TTM) 1.61 | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA 2.22 | Shares Outstanding 73136987 | Shares Floating 65726747 |
Shares Outstanding 73136987 | Shares Floating 65726747 | ||
Percent Insiders 4.92 | Percent Institutions 92.14 |
Upturn AI SWOT
OraSure Technologies Inc
Company Overview
History and Background
OraSure Technologies Inc. was founded in 1987, initially focusing on developing oral fluid collection devices. It gained prominence with its rapid HIV testing solutions and has since expanded into other infectious disease and substance abuse testing markets.
Core Business Areas
- Molecular Solutions: Develops, manufactures, and sells molecular sample collection and stabilization devices used for various diagnostic applications, including infectious disease and genetics testing.
- In-Vitro Diagnostic (IVD): Focuses on rapid diagnostic tests for infectious diseases, including HIV, hepatitis C, and COVID-19. This also includes point-of-care and at home tests.
Leadership and Structure
The company is led by its CEO, Lisa M. Nibauer. The organizational structure follows a functional model with departments for R&D, Manufacturing, Sales & Marketing, and Finance.
Top Products and Market Share
Key Offerings
- OraQuick HIV Self-Test: A rapid, over-the-counter HIV test that provides results in 20 minutes. While specific market share data varies, OraSure is a major player in the at-home HIV testing market. Competitors include Abbott and bioLytical Laboratories.
- OraCollect Dx: A self-collection device for oral fluid samples used in molecular diagnostics, particularly for infectious disease testing and genomics. The market share for this product is growing, particularly in telehealth. Competitors include DNA Genotek and Spectrum Solutions.
- InteliSwab COVID-19 Rapid Test: A rapid antigen self-test used to detect COVID-19 at home. While there was a significant decline in COVID-19 testing, the company still offers the test through various channels and markets. Competitors include Abbott and QuidelOrtho.
Market Dynamics
Industry Overview
The diagnostics industry is experiencing growth driven by increasing demand for rapid, point-of-care testing, particularly in infectious diseases. Molecular diagnostics is also expanding due to advances in genomics and personalized medicine. The COVID-19 pandemic significantly impacted the market, creating a surge in demand for testing, but this demand has declined.
Positioning
OraSure holds a strong position in the rapid HIV testing market and is expanding its presence in molecular diagnostics sample collection. Its competitive advantages include its established brand recognition and proprietary oral fluid collection technology.
Total Addressable Market (TAM)
The global molecular diagnostics market is projected to reach hundreds of billions USD in the coming years. OraSure is positioned to capture a share of this TAM through its OraCollect Dx product and ongoing innovation.
Upturn SWOT Analysis
Strengths
- Established brand recognition
- Proprietary oral fluid collection technology
- Strong distribution network
- Focus on rapid diagnostics
Weaknesses
- Reliance on a few key products
- Sensitivity to changes in infectious disease trends
- Fluctuations in COVID testing revenue
- Cost of goods sold has increased as a percentage of net product revenues
Opportunities
- Expansion into new diagnostic markets (e.g., cancer screening)
- Growth in molecular diagnostics and personalized medicine
- Increased adoption of telehealth and at-home testing
- Partnerships and collaborations with other healthcare companies
Threats
- Competition from larger diagnostic companies
- Changes in regulatory landscape
- Price pressure from commoditization of diagnostic tests
- Decline in COVID-19 testing demand
Competitors and Market Share
Key Competitors
- Abbott (ABT)
- Danaher (DHR)
- QuidelOrtho (QDEL)
Competitive Landscape
OraSure faces intense competition from larger, more diversified diagnostic companies. Its competitive advantage lies in its focus on rapid diagnostics and proprietary oral fluid collection technology. The smaller size makes it more nimble for product pivot. It must continue to innovate and expand into new markets to maintain its competitive position.
Major Acquisitions
CoreBiome
- Year: 2020
- Acquisition Price (USD millions): 20
- Strategic Rationale: Expanded the company's microbiome testing capabilities and market access.
Growth Trajectory and Initiatives
Historical Growth: OraSure experienced significant growth during the COVID-19 pandemic due to the demand for its rapid COVID-19 tests. However, revenue has declined as pandemic-related demand has waned. The company is now focusing on diversifying its product portfolio and expanding into new markets.
Future Projections: Analysts project that OraSure's revenue will grow in the coming years, driven by increased demand for its molecular diagnostics products and expansion into new markets. The company is expected to return to profitability in the next few years.
Recent Initiatives: Recent strategic initiatives include expanding its molecular diagnostics portfolio, investing in new manufacturing capacity, and forming partnerships with other healthcare companies.
Summary
OraSure Technologies Inc. is in a state of transition, moving away from COVID-19 testing reliance and focusing on its core strengths in oral fluid diagnostics. The company's established brand and innovative technology are assets, but it faces intense competition and the challenge of diversifying its revenue streams. Successful expansion into new markets and strategic partnerships are crucial for future growth. The company has been profitable in the past, but will be challenged for profitability moving forward.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Analyst Reports
- Company Website
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is based on estimates and may vary. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OraSure Technologies Inc
Exchange NASDAQ | Headquaters Bethlehem, PA, United States | ||
IPO Launch date 1986-11-12 | President, CEO & Director Ms. Carrie Eglinton Manner | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 501 | Website https://www.orasure.com |
Full time employees 501 | Website https://www.orasure.com | ||
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic and specimen collection devices and products in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, the company offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.